Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. LMT
9. SPY
10. SBUX

Go back to Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 8c

Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results

February 15, 2017 4:01 PM EST

WASHINGTON, Feb. 15, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2016.

"2016 was an exceptional year for Vanda as we continued to demonstrate strong growth in our commercial business and secured long-term exclusivity for Fanapt," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "In addition, our emerging pipeline with important 2017 milestones underscores Vanda's commitment to bringing important new treatment options to patients and the creation of shareholder value."

Key Highlights: HETLIOZ®... More